NATCO Pharma launches generic Posaconazole injection in India
Hyderabad: NATCO Pharma Limited announced that it has launched a generic version of Posaconazole Injection, 300 mg/16.7ml, under its brand POSANAT.
This is the first time an injection version of this drug available in India.
POSANAT will be available in 18.0 mg/ml strength, a formulation for intravenous (IV) use.
Posaconazole Injection is sold in the USA market by Merck under its brand name of NOXAFIL ®.
Posaconazole injection is an antifungal agent and used in patients who are at high risk of developing infections due to being severely immunocompromised, such as associated with stem cell transplant or from chemotherapy.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd